CLDN18 and gastroesophageal junction adenocarcinoma: Capecitabine + oxaliplatin (CapeOx) (every 3 weeks) in combination with zolbetuximab (800 mg/m2 loading dose then 600 mg/m2 every 3 weeks) (n = 254) or with placebo (n = 253) was studied in the NCT03653507, the GLOW trial, and the phase 3 double-blind randomized study for front-line treatment of CLDN18.2-positive, HER-2-negative, advanced GAC or GEJ adenocarcinoma patients [23].